Articles

Biogen licenses Mitsubishi’s MT-1303 for autoimmune diseases

Potential exists for development of the therapeutic in multiple sclerosis, ulcerative colitis and Crohn’s disease
Written byMel J. Yeates
| 3 min read

CAMBRIDGE, Mass.—Biogen has announced an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corp. (MTPC). MT-1303 is an oral compound that targets the sphingosine-1-phosphate (S1P) receptor.

According to MTPC’s website, MT-1303 is an S1P receptor functional antagonist, and by inhibiting the receptor function of the S1P receptor on the lymphocyte, it keeps lymphocytes sequestered in the lymph nodes to prevent them from contributing to autoimmune reactions. Due to this mechanism, this compound may be potentially effective for various autoimmune diseases. MTPC is currently conducting clinical trials for MT-1303 for multiple sclerosis, psoriasis, Crohn’s disease and systemic lupus erythematosus in Europe and Japan. The compound has also obtained results suggesting a profile possibly safer than that of the existing S1P receptor functional antagonists.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.